Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Joubert, Marisa K ^a   Deshpande, Meghana ^a,d   Yang, Jane ^a   Reynolds, Helen ^b   Bryson, Christine ^b,e   Fogg, Mark ^b   Baker, Matthew P ^b   Herskovitz, Jonathan ^a   Goletz, Theresa J ^c   Zhou, Lei ^a   Moxness, Michael ^a   Flynn, Gregory C ^a   Narhi, Linda O ^a   Jawa, Vibha ^a  

^a AMGEN INC   (United States)

^b Antitope Ltd   (United Kingdom)

^c AMGEN INC   (United States)

^d Eurofins Medinet Inc   (Germany)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GALACTOSE; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 2; MANNOSE; MONOCLONAL ANTIBODY; CYTOKINE;

AMINO ACID SEQUENCE; ARTICLE; BIOASSAY; BIOLOGICAL THERAPY; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; GLYCATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LIFESPAN; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENETICS; GLYCOSYLATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; POINT MUTATION; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; GLYCOSYLATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; POINT MUTATION; RISK ASSESSMENT; T-LYMPHOCYTES;

EID: 84983418557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159328     Document Type: Article

References (46)

1. U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2014). Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. Forms based on FDA Drugs guidance (FDA Maryland).
2. European Medicines Agency/Committee for Medicinal Products for Human Use (2007). Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (EMEA/CHMP London, UK).
3. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118: 42-50. PMID: 16260183
4. Koren E, Zuckerman LA, Mire-Sluis AR (2002) Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 3: 349-360. PMID: 12463417
5. Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10: 219-227. PMID: 17436557
6. Jaber A, Baker M (2007) Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 43: 1256-1261. PMID: 17118612
7. Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, et al. (2007) The Rebif new formulation story: it's not trials and error. Drugs R D 8: 335-348. PMID: 17963425
8. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, et al. (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287: 25266-25279. doi: 10.1074/jbc.M111.330902 PMID: 22584577
9. Telikepalli S, Shinogle HE, Thapa PS, Kim JH, Deshpande M, et al. (2015) Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting. J Pharm Sci 104: 1575-1591. doi: 10.1002/jps.24379 PMID: 25753756
10. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, et al. (2014) Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS One 9: e86322. doi: 10.1371/journal.pone.0086322 PMID: 24466023
11. Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, et al. (2012) Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine 30: 4859-4865. doi: 10.1016/j.vaccine.2012.05.002 PMID: 22609036
12. Haile LA, Puig M, Kelley-Baker L, Verthelyi D (2015) Detection of innate immune response modulating impurities in therapeutic proteins. PLoS One 10: e0125078. doi: 10.1371/journal.pone.0125078 PMID: 25901912
13. Kendal AR, Chen Y, Regateiro FS, Ma J, Adams E, et al. (2011) Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 208: 2043-2053. doi: 10.1084/jem.20110767 PMID: 21875958
14. Brinks V, Jiskoot W, Schellekens H (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28: 2379-2385. doi: 10.1007/s11095-011-0523-5 PMID: 21744171
15. Mosmann TR, Fong TA (1989) Specific assays for cytokine production by T cells. J Immunol Methods 116: 151-158. PMID: 2642947
16. Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, et al. (2015) Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res 32: 1383-1394. doi: 10.1007/s11095-014-1541-x PMID: 25319104
17. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, et al. (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48: 1267-1281. doi: 10.1016/j.jpba.2008.09.020 PMID: 18993008
18. Wang P, Sidney J, Dow C, Mothe B, Sette A, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4: e1000048. doi: 10.1371/journal.pcbi.1000048 PMID: 18389056
19. Welsh RM, Che JW, Brehm MA, Selin LK (2010) Heterologous immunity between viruses. Immunol Rev 235: 244-266. doi: 10.1111/j.0105-2896.2010.00897.x PMID: 20536568
20. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, et al. (2010) Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 137: 5-14. doi: 10.1016/j.clim.2010.06.018 PMID: 20708973
21. Pardeshi N, Ahmadi M, Fogg M, Baker M, Carpenter J (2015) Investigating the immunogenic potential of particles in intravenous solutions of infliximab. Poster presentation at the IABS 2nd Progress and Challenges in Protein Particles and Immunogenicity of Biotherapeutics 2015: Filling in the Gaps in Risk Evaluation and Mitigation Conference, Rockville, MD.
22. Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, et al. (2016) Immunogenicity of therapeutic protein aggregates. Journal of Pharmaceutical Sciences 105: 417-430. doi: 10.1016/j.xphs.2015.11.002 PMID: 26869409
23. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, et al. (2013) T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 149: 534-555. doi: 10.1016/j.clim.2013.09.006 PMID: 24263283
24. Yang J, Primack R, Frohn M, Wang W, Luan P, et al. (2015) Impact of glycation on antibody clearance. AAPS J 17: 237-244. doi: 10.1208/s12248-014-9694-4 PMID: 25413724
25. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO (2011) Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286: 25118-25133. doi: 10.1074/jbc.M110.160457 PMID: 21454532
26. Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, et al. (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27: 269-274. PMID: 17006705
27. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51: 534-542. PMID: 15389187
28. Ling ZD, Ziltener HJ, Webb BT, Matheson DS (1990) Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol 129: 95-103. PMID: 2364444
29. de la Rosa M, Rutz S, Dorninger H, Scheffold A (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34: 2480-2488. PMID: 15307180
30. Zhou L, Hoofring SA, Wu Y, Vu T, Ma P, et al. (2013) Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J 15: 30-40. doi: 10.1208/s12248-012-9408-8 PMID: 23054969
31. Xue L, Hickling T, Song R, Nowak J, Rup B (2016) Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin Exp Immunol 183: 102-113. doi: 10.1111/cei.12711 PMID: 26400440
32. Collen T, Douglas AJ, Paton DJ, Zhang G, Morrison WI (2000) Single amino acid differences are sufficient for CD4(+) T-cell recognition of a heterologous virus by cattle persistently infected with bovine viral diarrhea virus. Virology 276: 70-82. PMID: 11021996
33. Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, et al. (2015) The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res 32: 2344-2359. doi: 10.1007/s11095-015-1627-0 PMID: 25630815
34. Bukofzer S, Ayres J, Chavez A, Devera M, Miller J, et al. (2015) Industry perspective on the medical risk of visible particles in injectable drug products. PDA J Pharm Sci Technol 69: 123-139. doi: 10.5731/pdajpst.2015.01037 PMID: 25691720
35. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, et al. (2011) Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. J Biol Chem 286: 25134-25144. doi: 10.1074/jbc.M110.160440 PMID: 21518762
36. Barnard JG, Babcock K, Carpenter JF (2013) Characterization and quantitation of aggregates and particles in interferon-beta products: potential links between product quality attributes and immunogenicity. J Pharm Sci 102: 915-928. doi: 10.1002/jps.23415 PMID: 23233295
37. Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W (2012) Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 101: 187-199. doi: 10.1002/jps.22744 PMID: 21918983
38. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, et al. (2009) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98: 1201-1205. doi: 10.1002/jps.21530 PMID: 18704929
39. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, et al. (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28: 920-933. doi: 10.1007/s11095-010-0297-1 PMID: 20972611
40. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. Aaps J 8: E501-507. PMID: 17025268
41. Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100: 354-387. doi: 10.1002/jps.22276 PMID: 20740683
42. Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, et al. (2013) Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci 102: 3545-3555. doi: 10.1002/jps.23663 PMID: 23925953
43. Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC (2012) Rates and impact of human antibody glycation in vivo. Glycobiology 22: 221-234. doi: 10.1093/glycob/cwr141 PMID: 21930650
44. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. PMID: 9521319
45. Kzhyshkowska J, Gordon S (2009) Vesicular trafficking in immune cells. Immunobiology 214: 493-494. doi: 10.1016/j.imbio.2009.03.006 PMID: 19450897
46. Varin A, Gordon S (2009) Alternative activation of macrophages: immune function and cellular biology. Immunobiology 214: 630-641. doi: 10.1016/j.imbio.2008.11.009 PMID: 19264378